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Abstract
Background: Due to the unpredictable burden of pandemic influenza, the best strategy to manage testing, such as rapid or
polymerase chain reaction (PCR), and antiviral medications for patients who present with influenza-like illness (ILI) is
unknown.
Methodology/Principal Findings: We developed a set of computer simulation models to evaluate the potential economic
value of seven strategies under seasonal and pandemic influenza conditions: (1) using clinical judgment alone to guide
antiviral use, (2) using PCR to determine whether to initiate antivirals, (3) using a rapid (point-of-care) test to determine
antiviral use, (4) using a combination of a point-of-care test and clinical judgment, (5) using clinical judgment and
confirming the diagnosis with PCR testing, (6) treating all with antivirals, and (7) not treating anyone with antivirals. For
healthy younger adults (,65 years old) presenting with ILI in a seasonal influenza scenario, strategies were only cost-
effective from the societal perspective. Clinical judgment, followed by PCR and point-of-care testing, was found to be cost-
effective given a high influenza probability. Doubling hospitalization risk and mortality (representing either higher risk
individuals or more virulent strains) made using clinical judgment to guide antiviral decision-making cost-effective, as well
as PCR testing, point-of-care testing, and point-of-care testing used in conjunction with clinical judgment. For older adults
($65 years old), in both seasonal and pandemic influenza scenarios, employing PCR was the most cost-effective option,
with the closest competitor being clinical judgment (when judgment accuracy $50%). Point-of-care testing plus clinical
judgment was cost-effective with higher probabilities of influenza. Treating all symptomatic ILI patients with antivirals was
cost-effective only in older adults.
Conclusions/Significance: Our study delineated the conditions under which different testing and antiviral strategies may be
cost-effective, showing the importance of accuracy, as seen with PCR or highly sensitive clinical judgment.
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Introduction
Although prompt antiviral treatment may be able to improve
outcomes for adults infected by either seasonal or pandemic (such
as novel H1N1) influenza viruses, antiviral treatment is costly, $77
to $121 per patient (due to repackaging differences). Antivirals
may be particularly useful for older adults ($65 years old), who are
at greater risk for influenza complications [1]. Testing may help
distinguish influenza from other types of influenza-like illness (ILI)
[2]. Many clinicians use patient symptoms to identify those who
may have influenza and benefit from a course of antiviral therapy.
As with any test, clinical judgment is less than perfect and has
varying degrees of accuracy [3,4]. Testing for influenza, with
either rapid influenza tests or polymerase chain reaction (PCR),
may help better diagnose influenza and guide antiviral treatment
[5]. However, these tests also have associated costs and less than
perfect sensitivity and specificity. In fact, recent reports suggest
that currently available rapid tests have relatively low sensitivity in
detecting the novel influenza A (H1N1) strain [6,7,8,9]. Finally, in
pandemic scenarios, some clinicians may be inclined to administer
antivirals to everyone presenting with ILI if they believe that
morbidity and mortality risk are elevated.
Currently, no consensus exists over influenza testing of patients
presenting with ILI in seasonal or pandemic influenza scenarios
[10,11]. The optimal approach will minimize expected associated
costs while maximizing expected clinical effects, i.e., provide
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11284antiviral treatment to those who truly have influenza. Economic
modeling can help address this ongoing question and assist
clinicians in their decision making, third-party payors in their
insurance coverage policies, test manufacturers in their pricing
strategies, scientists in their test development, and public health
officials in their policy making. Economic value can be particularly
informative during an influenza pandemic when time is short,
available resources may be limited, and outcomes may be worse.
We developed a computer simulation model to compare the
potential economic impact of different testing and antiviral use
strategies for patients presenting to the clinic or emergency room
with ILI symptoms. Simulation runs examined both seasonal and
pandemic influenza scenarios and explored the effects of varying
the probability of a patient with ILI having influenza, test
sensitivity and specificity, clinical judgment sensitivity, patient age,
and the probability of influenza outcomes such as hospitalization
and mortality. Additional scenarios explored the decision for
higher-risk adults (i.e., double the risk of hospitalization and
mortality), older adults, and higher-risk older adults.
Methods
Model Structures
Figures 1 and 2 depict the general structure of our Monte Carlo
decision analytic computer simulation models, constructed using
TreeAge Pro 2009 (TreeAge Software, Williamstown, Massachu-
setts). Each simulation run for both the younger adults (ages 20 to
64) and older adults (ages 65 to 85) sent 5,000 simulated adults
5,000 times (i.e., 25,000,000 trials) through the model. These
models represented an outpatient presenting to the clinic or
emergency room with ILI and a clinician’s choice among the
following options:
N Clinical judgment alone to distinguish influenza from ILI to
guide antiviral use.
N Clinical judgment to decide and then confirming with PCR
testing.
N PCR test and treat if positive (for outpatient settings with PCR
readily available).
N Rapid (point-of-care) test and treat if positive.
N Point-of-care test and treat if positive and if negative use
clinical judgment to decide.
N Treat all patients with antivirals without testing (i.e., clinicians
give antivirals to everyone presenting with ILI).
N No antiviral treatment.
Separate scenarios explored the decision from the third-party
payor perspective (considering only direct costs of illness) and the
societal prospective (considering direct and indirect costs).
ILI had a probability of being influenza. Test results were
available in 24 hours (if test was available at time of visit) and
incorporated their corresponding sensitivities and specificities.
The effects of varying clinical judgment sensitivity (i.e., the ability
of clinicians to immediately detect a case of influenza without
utilizing tests) were explored. Antiviral treatment consisted of
75 mg of oseltamivir twice a day for five days and reduced the
length of influenza illness, hospitalization risk, and mortality.
Patients who received antivirals had a probability of side effects
[mainly gastrointestinal with attendant quality-adjusted life year
(QALY) decrements]. Additionally, there was a probability of
antiviral resistance. All patients who did not receive antivirals
or require hospitalization, self-treated with over-the-counter
medications.
The following equation calculated the incremental cost-
effectiveness ratio (ICER) of each strategy versus the comparator
(i.e., not giving anyone antiviral medications):
~
CostStategy{CostNoAntiviralMedications
EffectivenessStrategy{EffectivenessNoAntiviralMedications
Our model measured effectiveness in QALYs. A strategy was
considered cost-effective if the ICER was less than $50,000 per
quality-adjusted life-year (QALY).
Data Inputs
Table 1 lists the various data inputs for our model and the
corresponding distributions and data sources used. We used
triangular distributions for all of our utility variables and gamma,
beta, or triangular distributions for all other variables. For
variables which may have skewed distributions, such as costs,
gamma distributions were used [12]. For probabilities that
approximated normal distributions, we employed beta distribu-
tions which are bounded by 0 and 1, unlike normal distributions
which can generate values outside this interval [13]. When limited
data existed providing only the lower limit, and upper limit of a
variable’s value, we utilized triangular distributions. Where
possible, data inputs came from published meta-analyses. All costs
were in 2009 U.S. dollars, a 3% discount rate converted all costs
into 2009 values. Our model measured effectiveness in QALYs. A
healthy person accrued the total complement of their age-adjusted
QALYs. Influenza and hospitalization each caused different
decrements in QALYs accrued for their durations. Patients who
did not survive lost QALYs based on their quality-adjusted life
expectancies derived from the Human Mortality Database [14].
These future life-years were discounted by 3% per year.
Sensitivity Analyses
Sensitivity analyses determined the effects of varying different
parameter values individually throughout the ranges listed in
Table 1. Multi-dimensional sensitivity analyses were performed on
selected parameters. In particular, we examined the effects of
varying PCR test sensitivity (90%, 95%) and specificity (95%,
100%), the sensitivity (25%, 50%, 75%) and specificity (90%, 95%)
of the point-of-care test, and the sensitivity of clinical judgment
(25%, 50%, 75%) to represent differences in test performance in
both seasonal and pandemic influenza conditions. To understand
how results may change with more virulent circulating influenza
virus strain (twice as virulent) or higher risk patients (twice as prone
to hospitalization or death), sensitivity analyses varied the
probability of hospitalization and mortality from influenza
(respectively, up to two times that of seasonal influenza). Since
the true increased risk of hospitalization and death may be highly
variable under these circumstances, this sensitivity analysis was
done due to the actual probabilities of hospitalization and
mortality of pandemic influenza being unknown. The probability
of ILI being influenza was varied from 10% to 20% to 30%. In
addition, probabilistic (Monte Carlo) sensitivity analyses examined
the effects of varying all parameters along their possible ranges.
Results
Seasonal Influenza Scenarios with Baseline Morbidity and
Mortality
Table 2 (societal perspective) and Table S1 (third-party payor
perspective) show the ICER of each strategy versus the control (no
antiviral medications for any patients) among younger adults (ages
Influenza Test or Treat?
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11284Figure 1. Influenza testing base structure. a) clinical judgment b) PCR testing c) antivirals to all d) point-of-care testing.
doi:10.1371/journal.pone.0011284.g001
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PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11284Figure 2. Influenza testing base structure. e) clinical judgment then PCR testing f) point-of-care testing with clinical judgment. Antiviral and
influenza outcomes tree structures.
doi:10.1371/journal.pone.0011284.g002
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sensitivity analyses varying the sensitivity and specificity of different
testing strategies. In general, simulation runs suggested that routinely
using antivirals was not cost-effective (i.e., ICER was greater than
$50,000/QALY) in younger adults, even when guided by testing or
clinical judgment from the third party payor perspective. In Table 2,
the situations where the ICER was less than $50,000/QALY from
the societal perspective are designated in bold.
The Table 3 (societal perspective) and Table S2 (third-party
payor perspective) show the ICER of each strategy versus the
control (no antiviral medications for any patients) for older adults
(65+ years) in baseline seasonal influenza scenarios. As can be seen,
many of the testing strategies become cost-effective especially when
the probability of ILI being influenza increases to 20% and 30%.
Pandemic Influenza (More Severe Influenza Virus Strain)
or High Risk Patients (Higher Morbidity and Mortality)
Additional scenarios explored the effects of doubling influenza-
attributable hospitalization and death risks, which would corre-
Table 1. Data inputs for model variables.
Description (units) Variable Name in Figures Dis* Mean Standard Deviation Range Source
COSTS ($US)
Neuraminidase Inhibitor c 99.32 21.99 [26]
Clinic Visit D 104.77 69.14–140.70 [27]
Median Hourly Wage 16,52 [28]
Over the Counter Medications D 15.61 11.70–19.51 [26]
Hospitalization, 18–44 yrs c 3,643.13 785.07 [29]
Hospitalization, 45–64 yrs c 4,396.37 1,354.77 [29]
Hospitalization, 65–84 yrs c 5,332.08 528.32 [29]
Death in Hospital 5,000 - [30]
PCR Test 29 - Expert Opinion
Rapid Test 22 - Expert Opinion
DURATIONS (days)
Influenza 7-
Time Missed from Work D 3.2 1.5–4.9 [31]
Time Antivirals Reduce Symptoms D 1.4 1.0–2.0 [32]
UTILITIES (QALYs)
One Year of Life for Adults, 18–64 yrs 0.92 - [33]
One Year of Life for Adults, 65–85 yrs 0.84 - [33]
Utility/Day
Influenza-Like Illness (ILI) D 0.725 0.61–0 .84 [34,35]
Influenza no Hospitalization D 0.5956 0.5579–0.65 [30,36,37,38,39,40,41]
Influenza with Hospitalization D 0.40 0.38–0.50 [37,40,41]
Antiviral Side Effects D 0.835 0.77–0.90 [30,42]
PROBABILITIES
Antiviral Side Effects pSE b 0.126 0.0440 [43,44,45]
Antiviral Resistance pResistance D 0.02 0.004–0.05 [32,46,47,48,49]
Hospitalization Given Influenza, 65–84 yrs pHospitalization D 0.04 0.01–0.07 [1]
Hospitalization Given Influenza, 18–54 yrs pHospitalization D 0.004 0.001–0.007 [50]
Antiviral Efficacy in Reducing Hospitalization D 0.78 0.00–0.98 [18,19]
Influenza Mortality, 18–44 yrs pMortality 0.0105 - [29]
Influenza Mortality, 45–64 yrs pMortality 0.0235 - [29]
Influenza Mortality, 65–85 yrs pMortality 0.0441 - [29]
SENSITIVITY ANALYSIS Sensitivity Analysis Values
ILI being Influenza pInfluenza 0.10, 0.20, 0.20 [51]
Clinical Judgment Sensitivity pSensitivityCJ 0.25, 0.50, 0.75 [52]
PCR Sensitivity pSensitivityPCR 0.90, 0.95 [9,52,53]
PCR Specificity pSpecificityPCR 0.95, 1.00 [9,52,53]
Point of Care Sensitivity pSensitivityPoC 0.25, 0.50, 075 [6,7,8,9,52,54]
Point of Care Specificity pSpecificityPoC 0.90, 0.95 [6,7,8,9,52,54]
*Distribution Type: c=gamma, b=beta, D=triangular.
doi:10.1371/journal.pone.0011284.t001
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patient. Table 4 and Table S1 (lower half) show the ICERs of each
strategy versus the control (no antiviral medications for any
patients) for younger adults (ages 20 to 64). Using clinical
judgment (sensitivity $75%) to guide antiviral treatment emerged
as the most cost-effective option when the probability of influenza
was $10%. The closest competitor to clinical judgment was PCR
testing, followed by point-of-care testing.
Table 5 and Table S2 (lower half) show the ICERs of each
strategy versus the control (no antiviral medications for any
patients) for scenarios in which influenza hospitalization risk and
mortality were double that of seasonal influenza for older adults
(65+ years old). All strategies were found to be cost-effective,
except clinical judgment (25% sensitive) when the probability of
influenza was 20%. Employing PCR to guide antiviral initiation
emerged as the most cost-effective option, becoming dominant for
most conditions. The closest competitor to PCR was clinical
judgment, followed by point-of-care testing, point-of-care testing
in combination with clinical judgment, and clinical judgment
confirmed by PCR testing.
Comparison of All Strategies
For adults, clinical judgment emerged as the most cost-effective
strategy when influenza made up 30% of seasonal ILI cases from
the societal perspective; this was followed by PCR (ICER:
$50,864/QALY) and point-of-care testing (ICER: $342,873/
QALY compared to PCR). From the third-party payor perspective
and societal perspective at 10% influenza, the do-nothing strategy
was the best, followed by clinical judgment (ICER #$148,358/
QALY), point-of-care (ICER: #$202,127/QALY) and PCR
testing (ICER: #$94,165/QALY compared to point-of-care).
For pandemic influenza, clinical judgment ($20% influenza)
Table 2. Incremental cost-effectiveness ratios (in $US per quality-adjusted life-years) of different approaches to patients aged 20 to
64 years with influenza-like illness (ILI) from the societal perspective for seasonal influenza.
Probability of ILI being Influenza
Strategy 10% 20% 30%
Baseline Seasonal Influenza Hospitalization Risk and Mortality
Treat all with Antivirals Do Nothing 255,981–271,024 61,287–65,255
Clinical Judgment (25){ Do Nothing Do Nothing 1,350,402–1,792,375
Clinical Judgment (50) Do Nothing 286,577–290,692 53,840–59,494
Clinical Judgment (75) 131,522–201,789 Dominant Dominant
PCR Test (90/95)* 134,800–146,777 32,320–42,414 1,555–2,157
PCR Test (90/100) 115,838–123,300 22,079–25,240 Dominant
PCR Test (95/100) 103,145–104,566 18,363–21,762 Dominant
PCR Test (90/95)+CJ (25) Do Nothing 541,092–634,618 149,340–239,616
PCR Test (90/95)+CJ (50) Do Nothing 612,506–841,518 182,798–263,160
PCR Test (90/95)+CJ (75) Do Nothing 549,754–1,356,977 162,449–206,521
PCR Test (90/100)+CJ (25) Do Nothing 512,980–711,987 131,079–163,658
PCR Test (90/100)+CJ (50) Do Nothing 434,991–771,128 182,643–198,933
PCR Test (90/100)+CJ (75) Do Nothing 543,776–591,240 169,910–190,378
PCR Test (95/100)+CJ (25) Do Nothing 667,556–704,636 103,596–142,230
PCR Test (95/100)+CJ (50) Do Nothing 430,605–515,751 143,424–157,084
PCR Test (95/100)+CJ (75) Do Nothing 449,201–681,528 143,583–156,729
Point-of-Care Test (25/95) 625,601–1,039,207 193,685–234,868 120,186–124,282
Point-of-Care Test (50/95) 178,094–215,502 72,209–76,111 26,303–28,149
Point-of-Care Test (75/95) 108,820–126,429 27,469–33,194 Dominant
Point-of-Care Test (25/95)+CJ (25) Do Nothing 3,392,605–3,474,515 333,795–534,802
Point-of-Care Test (25/95)+CJ (50) Do Nothing 330,944–334,942 103,681–127,920
Point-of-Care Test (25/95)+CJ (75) 314,229–453,120 79,798–108,930 25,276–29,208
Point-of-Care Test (50/95)+CJ (25) Do Nothing 717,676–1,026,360 201,643–256,826
Point-of-Care Test (50/95)+CJ (50) Do Nothing 207,952–213,952 75,563–77,585
Point-of-Care Test (50/95)+CJ (75) 253,632–382,295 70,983–79,551 18,662–21,233
Point-of-Care Test (75/95)+CJ (25) Do Nothing 320,955–408,254 111,650–114,703
Point-of-Care Test (75/95)+CJ (50) 1,463,398–3,226,593 157,730–166,551 54,372–56,919
Point-of-Care Test (75/95)+CJ (75) 306,082–355,297 62,538–73,435 11,731–14,727
Comparator: Do nothing.
{(Sensitivity).
*(Sensitivity/Specificity).
Bold Text: Strategy is cost effective (ICER versus Do Nothing is ,$50,000 per QALY).
Bold and Italic Text: Strategy is economically dominant (costs less and is more effective than Do Nothing).
doi:10.1371/journal.pone.0011284.t002
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nothing, PCR (ICER: $37,286/QALY), then point-of-care testing
(dominated by PCR). From the third-party payor perspective, the
do nothing strategy emerged as the most cost-effective, then
clinical judgment ($47,841/QALY), and point-of-care testing
($202,124/QALY compared to clinical judgment).
Among older adults (65+ years old), PCR testing emerged as the
most cost-effective strategy from both perspectives, dominating all
others in both seasonal and pandemic scenarios. From the societal
perspective, when $20% of cases were influenza, clinical
judgment followed PCR as the next most cost-effective, then by
point-of-care (#$215,650/QALY compared to clinical judgment)
and point-of-care plus clinical judgment (#$14,998/QALY
compared to point-of-care alone). From the third-party payor
perspective, PCR testing was followed by the do nothing strategy,
clinical judgment ($16,545/QALY compared to doing nothing),
then point-of-care testing ($173,895/QALY compared to clinical
judgment) for seasonal influenza. In a pandemic influenza
scenario, PCR testing dominated, followed by clinical judgment,
and point-of-care testing (#$287,530/QALY compared to clinical
judgment).
Discussion
Our study results suggest that for healthy younger adults (ages
20 to 64) from the third-party payor perspective, antiviral costs
outweigh the potential benefits of testing or antiviral use as long as
the virus has the same virulence as seasonal influenza. From the
societal perspective, PCR testing and highly sensitive clinical
judgment are cost-effective when influenza constitutes $20% of
ILI cases. For more virulent circulating virus strains or for higher-
risk patients, clinical judgment $50% sensitive, PCR, point-of-
Table 3. Incremental cost-effectiveness ratios (in $US per quality-adjusted life-years) of different approaches to patients aged 65 to
85 years with influenza-like illness (ILI) from the societal perspective for seasonal influenza.
Probability of ILI being Influenza
Strategy 10% 20% 30%
Baseline Seasonal Influenza Hospitalization Risk and Mortality
Treat all with Antivirals 60,028–84,119 22,841–33,040 11,783–16,158
Clinical Judgment (25){ 285,620–421,268 92,675–151,473 51,643–62,050
Clinical Judgment (50) 64,445–96,812 22,952–29,547 11,589–16,857
Clinical Judgment (75) 15,611–21,345 5,135–6,963 1,400–2,396
PCR Test (90/95)* 22,282–30,188 10,377–13,514 6,112–6,899
PCR Test (90/100) 19,872–28,254 9,315–11,795 4,823–6,406
PCR Test (95/100) 18,892–25,540 8,283–10,859 4,526–5,519
PCR Test (90/95)+CJ (25) 97,191–122,508 41,190–52,291 21,682–34,376
PCR Test (90/95)+CJ (50) 112,567–151,452 37,727–53,910 23,402–29,228
PCR Test (90/95)+CJ (75) 103,131–146,857 40,487–58,018 22,282–29,423
PCR Test (90/100)+CJ (25) 83,722–130,766 41,423–44,423 23,790–29,753
PCR Test (90/100)+CJ (50) 92,260–121,667 38,334–54,178 23,272–30,098
PCR Test (90/100)+CJ (75) 102,150–139,094 38,725–53,723 21,938–31,056
PCR Test (95/100)+CJ (25) 71,334–114,795 32,281–51,579 21,760–28,657
PCR Test (95/100)+CJ (50) 87,555–130,347 35,535–46,654 21,642–28,646
PCR Test (95/100)+CJ (75) 87,265–126,752 37,490–50,604 21,723–27,774
Point-of-Care Test (25/95) 86,911–88,159 30,347–37,452 24,732–26,032
Point-of-Care Test (50/95) 38,060–48,071 16,708–21,038 8,795–12,718
Point-of-Care Test (75/95) 22,367–30,731 9,280–13,839 4,733–6,090
Point-of-Care Test (25/95)+CJ (25) 188,184–299,894 68,453–89,056 36,948–49,960
Point-of-Care Test (25/95)+CJ (50) 87,471–110,599 32,429–44,525 17,936–23,989
Point-of-Care Test (25/95)+CJ (75) 43,839–50,862 16,911–21,976 8,768–11,795
Point-of-Care Test (50/95)+CJ (25) 124,841–148,754 42,529–57,340 23,804–31,963
Point-of-Care Test (50/95)+CJ (50) 61,417–92,954 25,539–33,208 14,557–19,005
Point-of-Care Test (50/95)+CJ (75) 34,915–49,613 14,748–19,180 7,940–10,148
Point-of-Care Test (75/95)+CJ (25) 85,786–118,320 33,122–42,735 18,404–23,233
Point-of-Care Test (75/95)+CJ (50) 58,798–73,172 21,361–30,208 11,958–16,030
Point-of-Care Test (75/95)+CJ (75) 32,920–42,902 13,268–17,098 7,130–9,215
Comparator: Do nothing.
{(Sensitivity).
*(Sensitivity/Specificity).
Bold Text: Strategy is cost effective (ICER versus Do Nothing is ,$50,000 per QALY).
Bold and Italic Text: Strategy is economically dominant (costs less and is more effective than Do Nothing).
doi:10.1371/journal.pone.0011284.t003
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clinical judgment were cost-effective (societal perspective) but only
when influenza constitutes at least 20% of all ILI cases. While
clinicians may be tempted to do so, treating all younger adult ILI
patients with antivirals is unlikely to be a cost-effective approach.
Findings were quite different for older adults (65+ years old).
Routine PCR testing of ILI cases seems cost-effective when the
probability of ILI being influenza is at least 10%. This presumes
that PCR is available at the time of the clinic visit, results are
rapidly available, and, if the test is positive, antiviral medications
are initiated within 48 hours, which may not be feasible in many
settings. Moreover, this assumed that testing every infected person
would not overwhelm laboratory facilities. Clinical judgment
$50% sensitive also appears to be cost-effective in both seasonal
and pandemic scenarios. Point-of-care testing in combination with
clinical judgment and using PCR to confirm clinical judgment
were cost-effective when $20% of ILI was influenza. All testing
strategies were cost-effective from the societal perspective.
Treating all older adults with antivirals may be a cost-effective
option as well.
For patients at much higher risk for complications, employing
PCR emerged as the most cost-effective option with clinical
judgment being the closest competitor but only when judgment
sensitivity reached or exceeded 50%. Complication risk may also
be elevated in pandemic scenarios with a more virulent circulating
strain. In a pandemic scenario, prescribing antivirals to all
symptomatic patients may be warranted for older adults but not
younger adults.
The performance of clinical judgment (as well as that of other
testing strategies) depends on the definition of ILI. The more
lenient the definition of ILI, the lower the probability of ILI being
influenza will be. Our study assumed the current Centers for
Table 4. Incremental cost-effectiveness ratios (in $US per quality-adjusted life-years) of different approaches to patients aged 20 to
64 years with influenza-like illness (ILI) from the societal perspective for pandemic influenza or high risk patients.
Probability of ILI being Influenza
Strategy 10% 20% 30%
Pandemic or High Risk Patients (2x Seasonal Influenza Hospitalization Risk and Mortality)
Treat all with Antivirals 344,799–592,966 60,250–84,750 17,901–23,898
Clinical Judgment (25) Do Nothing 390,342–789,151 160,149–373,427
Clinical Judgment (50) 269,233–411,339 75,155–81,362 18,668–25,379
Clinical Judgment (75) 37,503–45,934 Dominant Dominant
PCR Test (90/95) 62,190–63,018 12,819–16,495 Dominant
PCR Test (90/100) 50,400–51,477 7,847–10,767 Dominant
PCR Test (95/100) 43,512–43,801 6,072–8,740 Dominant
PCR Test (90/95)+CJ (25) 422,205–688,019 139,829–172,092 62,417–65,315
PCR Test (90/95)+CJ (50) 676,451–2,876,402 138,226–140,685 51,234–86,507
PCR Test (90/95)+CJ (75) 986,507–1,234,361 126,403–184,271 57,336–74,509
PCR Test (90/100)+CJ (25) 547,979–774,875 109,323–292,613 50,547–55,795
PCR Test (90/100)+CJ (50) 735,287–1,797,558 122,160–181,200 52,694–78,051
PCR Test (90/100)+CJ (75) 935,033–1,054,990 125,255–161,079 59,849–68,330
PCR Test (95/100)+CJ (25) 249,055–575,055 148,139–152,896 59,7356–74,683
PCR Test (95/100)+CJ (50) 581,611–1,407,688 129,831–140,404 43,852–56,130
PCR Test (95/100)+CJ (75) 429,612–519,042 123,864–142,654 50,019–70,622
Point-of-Care Test (25/95) 166,899–242,218 87,611–138,701 51,993–56,218
Point-of-Care Test (50/95) 90,359–130,079 27,887–36,463 8,827–10,913
Point-of-Care Test (75/95) 51,637–66,850 10,189–12,618 Dominant
Point-of-Care Test (25/95)+CJ (25) Do Nothing 236,096–384,279 156,413–171,915
Point-of-Care Test (25/95)+CJ (50) 381,699–416,699 103,613–105,420 40,661–53,021
Point-of-Care Test (25/95)+CJ (75) 102,697–168,367 33,071–40,082 7,576–9,994
Point-of-Care Test (50/95)+CJ (25) 988,213–1,909,470 154,926–183,070 69,634–73,471
Point-of-Care Test (50/95)+CJ (50) 231,581–310,961 69,986–75,760 26,809–37,315
Point-of-Care Test (50/95)+CJ (75) 110,861–134,020 26,833–33,309 4,996–7,811
Point-of-Care Test (75/95)+CJ (25) 361,604–761,138 97,237–106,912 39,757–47,102
Point-of-Care Test (75/95)+CJ (50) 214,597–261,459 56,607–69,742 18,622–23,655
Point-of-Care Test (75/95)+CJ (75) 93,714–109,034 22,917–29,311 3,028–4,733
Comparator: Do nothing.
{(Sensitivity).
*(Sensitivity/Specificity).
Bold Text: Strategy is cost effective (ICER versus Do Nothing is ,$50,000 per QALY).
Bold and Italic Text: Strategy is economically dominant (costs less and is more effective than Do Nothing).
doi:10.1371/journal.pone.0011284.t004
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$100uF and cough and/or sore throat, in the absence of a known
cause other than influenza [15,16]. The optimal influenza testing
strategy may be different depending on when during an epidemic
a patient presents with ILI. As our study has shown, the economic
value of each strategy is sensitive to the proportion of ILI that is
influenza. Early in an epidemic, this proportion may be rather low.
However, this proportion increases as the epidemic reaches its
peak and then starts to decrease. Therefore, real-time awareness of
local epidemiologic data (e.g., percent ILI that is influenza), may
help decision making [10,17].
Our results are consistent with studies suggesting that
neuraminidase inhibitors have modest efficacy and should be
optional for healthy adults during typical influenza seasons yet
recommended for high risk adults and epidemic situations with
more virulent strains [17,18,19]. However, not all studies are in
agreement, with some showing oseltamivir use to be cost-effective
for healthy adults, children, elderly, and individuals at increased
risk for complications [20]. Sintchenko et al suggested that low-risk
patients with ILI should be tested before treated with antivirals
and that high-risk patients would benefit from prompt treatment
[21]. Our study suggests that for healthy younger adults doing
nothing is favorable until influenza constitutes 20% or more of ILI
cases, when testing becomes favorable. By contrast, testing is
consistently more cost-effective than doing nothing for older
adults.
The CDC state that most persons with uncomplicated H1N1
influenza do not need testing and notes that when a decision is
made to use antiviral treatment for influenza, treatment should be
initiated as soon as possible without waiting for influenza test
results [22]. Indeed, antiviral treatment is more effective when
administered as early as possible in the course of illness. CDC has
Table 5. Incremental cost-effectiveness ratios (in $US per quality-adjusted life-years) of different approaches to patients aged 65 to
85 years with influenza-like illness (ILI) from the societal perspective for pandemic influenza or high risk patients.
Probability of ILI being Influenza
Strategy 10% 20% 30%
Pandemic or High Risk Patients (2x Seasonal Influenza Hospitalization Risk and Mortality)
Treat all with Antivirals 11,320–15,765 3,076–4,227 318–467
Clinical Judgment (25) 47,436–60,652 18,125–22,159 8,972–11,366
Clinical Judgment (50) 11,890–15,621 3,175–4,146 301–583
Clinical Judgment (75) 1,324–2,136 Dominant Dominant
PCR Test (90/95)* 3,628–4,988 Dominant Dominant
PCR Test (90/100) 2,789–3,750 Dominant Dominant
PCR Test (95/100) 2,463–3,142 Dominant Dominant
PCR Test (90/95)+CJ (25) 23,745–26,472 9,311–9,902 3,446–4,164
PCR Test (90/95)+CJ (50) 20,588–29,728 7,094–10,090 6,472–9,101
PCR Test (90/95)+CJ (75) 20,326–27,346 21,115–26,993 19,304–25,901
PCR Test (90/100)+CJ (25) 19,423–26,903 8,901–9,442 2,973–4,390
PCR Test (90/100)+CJ (50) 20,453–27,160 7,303–9,532 3,118–4,160
PCR Test (90/100)+CJ (75) 21,115–26,993 7,242–9,784 3,027–4,139
PCR Test (95/100)+CJ (25) 18,466–25,825 6,491–8,675 3,062–3,314
PCR Test (95/100)+CJ (50) 18,581–24,773 6,472–9,010 2,775–3,285
PCR Test (95/100)+CJ (75) 19,304–25,901 6,741–8,780 2,629–3,699
Point-of-Care Test (25/95) 16,469–27,039 6,874–8,395 3,155–4,230
Point-of-Care Test (50/95) 6,623–8,804 1,491–1,888 Dominant
Point-of-Care Test (75/95) 3,219–4,145 Dominant Dominant
Point-of-Care Test (25/95)+CJ (25) 35,678–44,618 13,479–16,596 6,790–8,967
Point-of-Care Test (25/95)+CJ (50) 15,794–21,438 5,723–7,582 1,912–2,597
Point-of-Care Test (25/95)+CJ (75) 7,103–9,563 1,506–1,999 Dominant
Point-of-Care Test (50/95)+CJ (25) 22,777–31,938 8,294–11,270 3,428–4,805
Point-of-Care Test (50/95)+CJ (50) 15,794–21,438 5,723–7,582 1,912–2,597
Point-of-Care Test (50/95)+CJ (75) 7,103–9,563 1,506–1,999 Dominant
Point-of-Care Test (75/95)+CJ (25) 16,316–21,394 5,492–7,410 1,871–2,511
Point-of-Care Test (75/95)+CJ (50) 10,183–14,170 2,899–4,208 478–555
Point-of-Care Test (75/95)+CJ (75) 5,741–7,635 826–1,079 Dominant
Comparator: Do nothing.
{(Sensitivity).
*(Sensitivity/Specificity).
Bold Text: Strategy is cost effective (ICER versus Do Nothing is ,$50,000 per QALY).
Bold and Italic Text: Strategy is economically dominant (costs less and is more effective than Do Nothing).
doi:10.1371/journal.pone.0011284.t005
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who is at higher risk for influenza and its complications [23]. CDC
also has recommendations for antiviral usage [24]. Our analysis
adds to the CDC guidelines by showing the importance of either
highly sensitive clinical judgment or PCR.
Unfortunately, clinical diagnosis of influenza is problematic. In
the Rational Clinical Examination Series, the authors reported
that clinical findings identify patients with ILI but are not
particularly useful for confirming or excluding the diagnosis of
influenza [10]. Factors decreasing the likelihood of influenza
included the absence of fever, cough, or nasal congestion, findings
with likelihood ratios (LR) ,0.5. In studies limited to patients aged
60 years or older, the combination of fever, cough, and acute onset
had the highest LR of 5.4.
The Infectious Disease Society of America (IDSA) released
guidelines in 2009 for seasonal influenza that indicate which
persons should be tested for influenza if the result will influence
clinical management, including initiation of antiviral medications
[25]. IDSA recommends treatment for seasonal influenza for
persons who meet the specified criteria, including those with
laboratory-confirmed or highly suspected influenza virus infection
at high risk of developing complications and are within 48 hours
after symptom onset. According to IDSA, treatment should be
considered for outpatients with laboratory-confirmed or highly
suspected influenza virus infection who are not at increased risk of
complications, whose onset of symptoms is less than 48 hours
before presentation, and who wish to shorten the duration of
illness and further reduce their relatively low risk of complications.
IDSA revisited these guidelines in light of the pandemic.
Limitations
No computer model can fully represent every single possible
influenza event and outcome. Models, by definition, are
simplifications of real life. While in our study, we explored some
possible higher-risk patient scenarios, fully representing the wide
range of possible increases in hospitalization risk and mortality is
difficult. The impact of co-morbidities can be variable and
unexpected, which may increase their corresponding resource use
(e.g., mechanical ventilation). This risk varies depending on the
underlying condition (asthma vs. pregnancy vs. cardiovascular
disease), the number of comorbidities, and the timing of antiviral
initiation. Clear definitions of high risk groups are evolving as
pandemics progress; for example, obesity has been considered in
some studies to confer increased risk while HIV infection has not
conferred as much increased risk as initially thought. There is a
dearth of data on how delaying administration of antivirals will
reduce antiviral efficacy, especially when patients present to the
clinic or emergency room at different stages of infection. To
remain conservative about the benefits of antivirals, our model did
not include the potential ability of antivirals to reduce transmis-
sion. It can be challenging to model transmission effects on a
patient presenting to a clinic or emergency room, who may have
any number of contact rates and patterns before and after the visit.
Moreover, there remains debate over the efficacy of antivirals in
preventing transmission.
Conclusions
Our study delineated the conditions under which different
testing and antiviral strategies may be cost-effective. For healthy
adults aged 20 to 64 years with seasonal influenza, none of the
tested strategies were found to be cost-effective from the third-
party payor perspective. When hospitalization risk and mortality
were doubled, using clinical judgment ($50% sensitive) to guide
antiviral initiation emerged as the most cost-effective option with
PCR testing being the closest competitor but only when at least
20% of ILI cases were influenza. Among older adults (65+ years
old), employing PCR to guide antiviral initiation emerged as the
most cost-effective option with the closest competitor being clinical
judgment when judgment sensitivity was at least 50%. Treating all
ILI patients with antivirals appeared to be cost-effective only in
older adults.
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